Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient

Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Nicoletta Colombo The choice of second-line chemotherapy in patients with recurrent ovarian cancer (ROC) is complex, with several factors to be considered, the most important of which is the length of the platinum-free treatment interval (PFI). Recently ROC patients have been further stratified into platinum sensitive (PS), partially platinum sensitive (PPS) and platinum resistant (PR) subgroups depending on the length of the PFI. Response to second-line therapy, progression-free survival (PFS) and overall survival (OS) are linked to the PFI, all of them improving as the PFI increases. Consequently, there is increasing interest in PFI extension strategies with platinum-free therapeutic options. Such strategies are currently being studied in those patients with partially platinum-sensitive disease (PFI 6–12 months), as the treatment of these patients remains clinically challenging. A non-platinum option, trabectedin + pegylated liposomal doxorubicin (PLD) combination, has been evaluated in ROC patients in the pivotal phase III OVA-301 study. The OVA-301 study differed from previous trials in the same setting as it included only patients who were not expected to benefit from or who were ineligible for or who were unwilling to receive retreatment with platinum-based chemotherapy, including those with PPS and PR disease. Subset analysis of patients with PPS disease ...
Source: European Journal of Cancer Supplements - Category: Cancer & Oncology Source Type: research